Last Updated: September 28, 2026

ICATIBANT ACETATE Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Icatibant Acetate, and when can generic versions of Icatibant Acetate launch?

Icatibant Acetate is a drug marketed by Alembic, Caplin, Cipla, Eugia Pharma, Fresenius Kabi Usa, Glenmark Pharms Ltd, Jiangsu Hansoh Pharm, Nang Kuang Pharm Co, Teva Pharms Usa, and Wilshire Pharms Inc. and is included in ten NDAs.

The generic ingredient in ICATIBANT ACETATE is icatibant acetate. Nine suppliers are listed for this compound. Additional details are available on the icatibant acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Icatibant Acetate

A generic version of ICATIBANT ACETATE was approved as icatibant acetate by TEVA PHARMS USA on July 15^th, 2019.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for ICATIBANT ACETATE?
What are the global sales for ICATIBANT ACETATE?
What is Average Wholesale Price for ICATIBANT ACETATE?

Summary for ICATIBANT ACETATE

US Patents:	0
Applicants:	10
NDAs:	10

Paragraph IV (Patent) Challenges for ICATIBANT ACETATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FIRAZYR	Injection	icatibant acetate	10 mg/mL	022150	2	2015-08-25

US Patents and Regulatory Information for ICATIBANT ACETATE

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alembic	ICATIBANT ACETATE	icatibant acetate	INJECTABLE;SUBCUTANEOUS	213773-001	Jun 14, 2024	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Jiangsu Hansoh Pharm	ICATIBANT ACETATE	icatibant acetate	INJECTABLE;SUBCUTANEOUS	211021-001	Mar 9, 2020	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Eugia Pharma	ICATIBANT ACETATE	icatibant acetate	INJECTABLE;SUBCUTANEOUS	213521-001	Aug 14, 2023	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.